English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Uterine carcinosarcoma (UCS) is a relatively rare tumor in gynecologic malignancy that comprises less than 5% of uterine cancers, but it often shows an aggressive phenotype that has contributed to 30% of uterine cancer deaths [1]. Ovarian carcinosarcoma (OCS) is a very rare ovarian tumor that accounts for only 1% of ovarian cancer, and is composed of both malignant epithelial and mesenchymal elements, as well as UCS [1,2]. Prognosis of UCS and OCS is poor because up to 2/3 of patients present with advanced stage [2,3]. Currently, prognostic factors of carcinosarcoma (CS) are not well defined, but published reports have suggested pathological features and age as prognostic factors [4,5,6]. Previously, gynecological CS had been considered and treated as a sarcoma subtype [7]. However, CS is now recognized as a metaplastic carcinoma with the sarcoma component resulting from dedifferentiation of the carcinoma component [8], and therefore it is recommended that CS is treated similar to high-risk endometrial or ovarian carcinoma [9]. While combination chemotherapy of ifosfamide and paclitaxel is currently considered as a standard chemotherapy for UCS [10], an alternative combination is carboplatin and paclitaxel. The efficacy of combination carboplatin and paclitaxel has been reported in several phase II trials, and this combination appears to be better tolerated [11,12]. Based on these results, the combination of carboplatin plus paclitaxel is often used as a standard first line treatment for UCS or OCS, but second line treatment options are limited.

Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study